MPL exon 10 mutations in Irish patients with a suspected myeloproliferative neoplasm
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
MPL exon 10 mutations in Irish patients with a suspected myeloproliferative neoplasm ; volume:20 ; day:01 ; month:02 ; year:2021
EXCLI journal ; 20 (01.02.2021)
- Urheber
-
Lee Tokar, Lisa
Kearney, Laura
Langabeer, Stephen E.
- DOI
-
10.17179/excli2021-3454
- URN
-
urn:nbn:de:101:1-2021051813361747915230
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lee Tokar, Lisa
- Kearney, Laura
- Langabeer, Stephen E.
Ähnliche Objekte (12)
Optimizing Care: Integrative Oncology in Myeloproliferative Neoplasm
Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression
Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
Concurrent chronic myeloid leukemia and CALR-mutated myeloproliferative neoplasm
Cerebral salt wasting in a patient with myeloproliferative neoplasm
The Myeloproliferative Neoplasm Landscape: A Patient’s Eye View
Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm
Rare gene fusion rearrangement SPTNB1-PDGFRB in an atypical myeloproliferative neoplasm
A Case of Acquired von Willebrand Disease Secondary to Myeloproliferative Neoplasm
Order-of-Mutation Effects on Cancer Progression: Models for Myeloproliferative Neoplasm
p27KIP1 and PTEN cooperate in myeloproliferative neoplasm tumor suppression in mice
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
Optimizing Care: Integrative Oncology in Myeloproliferative Neoplasm
Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression
Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
Concurrent chronic myeloid leukemia and CALR-mutated myeloproliferative neoplasm
Cerebral salt wasting in a patient with myeloproliferative neoplasm
The Myeloproliferative Neoplasm Landscape: A Patient’s Eye View
Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm
Rare gene fusion rearrangement SPTNB1-PDGFRB in an atypical myeloproliferative neoplasm
A Case of Acquired von Willebrand Disease Secondary to Myeloproliferative Neoplasm
Order-of-Mutation Effects on Cancer Progression: Models for Myeloproliferative Neoplasm
p27KIP1 and PTEN cooperate in myeloproliferative neoplasm tumor suppression in mice
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
Optimizing Care: Integrative Oncology in Myeloproliferative Neoplasm
Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression
Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
Concurrent chronic myeloid leukemia and CALR-mutated myeloproliferative neoplasm
Cerebral salt wasting in a patient with myeloproliferative neoplasm
The Myeloproliferative Neoplasm Landscape: A Patient’s Eye View
Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm
Rare gene fusion rearrangement SPTNB1-PDGFRB in an atypical myeloproliferative neoplasm
A Case of Acquired von Willebrand Disease Secondary to Myeloproliferative Neoplasm
Order-of-Mutation Effects on Cancer Progression: Models for Myeloproliferative Neoplasm
p27KIP1 and PTEN cooperate in myeloproliferative neoplasm tumor suppression in mice